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ABSTRACT Platelet-derived growth factor (PDGF) and
phorbol 12-mrnristate 13-acetate (PMA) decrease high affinity
binding of 1 I-labeled epidermal growth factor (EGF) and
potentiate mitogenesis in BALB/c 3T3 cells, and both have
been shown to induce the phosphorylation of the EGF receptor
at threonine residues. These similarities suggest that the actions
of PDGF on EGF binding may be mediated by protein kinase
C, the cellular effector of PMA. We show that in density-
arrested BALB/c 3T3 cells PDGF and PMA induce a rapid,
transient, cycloheximide-independent loss of EGF binding
activity. As has been previously shown for PDGF, the ability of
PMA to reduce EGF binding was enhanced by cholera toxin,
a potent activator of adenylate cyclase. In contrast to PMA,
however, PDGF induced a further reduction in EGF binding
that was strictly dependent upon continued protein synthesis.
Furthermore, PDGF effectively reduced EGF binding in cells
refractory to PMA. Cells desensitized to PMA, presumably due
to the loss of protein kinase C activity, also remained mitogeni-
cally responsive to PDGF. These data suggest that the mech-
anism by which PDGF modulates EGF binding differs from
that ofPMA and thus, at least in part, is independent of protein
kinase C.
Platelet-derived growth factor (PDGF) enhances the mito-
genic activity of epidermal growth factor (EGF) in a variety
of cell lines (1-4). A target common to both PDGF and EGF,
and thus a potential mediator of PDGF-induced EGF sensi-
tization, is the EGF receptor. The binding of EGF to its
membrane receptors, an event essential for its mitogenic
action, and the subsequent internalization and ultimate deg-
radation of ligand-bound receptors are well-characterized
phenomena (reviewed in ref. 5). PDGF acts indirectly on
EGF receptors-i.e., PDGF binds to sites distinct from the
EGF binding site-to decrease the number of high affinity
EGF receptors (6-11). Consequently, cellular capacity to
bind EGF is reduced following treatment with PDGF.
When added to intact cells, PDGF induces the phospho-
rylation of the EGF receptor at threonine-654 (12). Threo-
nine-654 is also phosphorylated in vivo in response to phorbol
12-myristate 13-acetate (PMA, ref. 54), and a region contain-
ing this site is phosphorylated in vitro by protein kinase C
(13), the putative binding site for and cellular mediator of
PMA (14). PDGF indirectly activates protein kinase C by
stimulating the formation of its endogenous activator, diacyl-
glycerol (15-18). These observations, coupled with the find-
ing that PMA also reduces EGF binding (19-32), suggest that
PDGF and PMA decrease the number or affinity of EGF
receptors via a common mechanism-namely, the activation
of protein kinase C and the subsequent phosphorylation of
EGF receptors at threonine residues. Furthermore, this may
be the mechanism by which both PDGF and PMA (33, 34)
promote the EGF-induced proliferation of many cell lines.
Density-arrested BALB/c 3T3 cells are not induced to
proliferate by EGF unless they are first briefly exposed to
PDGF orPMA (2, 33). It has been proposed that these agents
render quiescent cells "competent" to respond to EGF and
to other mitogens contained in platelet-poor plasma (35).
Density-arrested cells treated with PDGF have a reduced
capacity to bind EGF (7, 36), as do proliferating cells treated
with PMA (22). We compared the effects ofPDGF and PMA
on EGF binding in quiescent BALB/c 3T3 cells and assessed
the effects of cycloheximide, cholera toxin, and PMA pre-
treatment on the PDGF- and PMA-induced responses. The
data reveal significant differences between the actions of
PDGF and PMA and suggest that the mechanism by which
PDGF modulates EGF receptors differs, at least in part, from
that of PMA.
MATERIALS AND METHODS
Cell Culture. Stock cultures of BALB/c 3T3 cells (clone
A31) were grown in Dulbecco-Vogt modified Eagle's medi-
um supplemented with 10% (vol/vol) calf serum, 4 mM
L-glutamine, penicillin at 50 Units/ml, and streptomycin at 50
;zg/ml in, humidified 5% C02/95% air at 370C. For all
experimental procedures, cells were grown to confluency in
serum-containing medium and used 2-3 days after growth
cessation.
EGF Binding. Cells in 35-mm culture dishes were trans-
ferred to 0.5 ml of binding medium (Hank's balanced salt
solution supplemented with 0.1% bovine serum albumin and
30 mM Hepes, pH 7.4) containing 1251-labeled EGF (1-2
ng/ml). Following a 2.5-hr incubation at 40C, the cultures
were rinsed three times with binding medium and solubilized
in 0.1% NaOH containing 1% NaDodSO4. The amount of
cell-bound radioactivity was determined using a gamma
counter and was corrected for nonspecific binding occurring
in the presence of EGF (1 pug/ml).
DNA Synthesis Assay. Cells in 35-mm culture dishes were
incubated with [3H]thymidine (5 tCi/ml; 1 Ci = 37 GBq) for
24 hr, rinsed with phosphate-buffered saline, and treated
twice for 10 min with 5% (wt/vol) trichloroacetic acid.
Trichloroacetic acid-insoluble material was solubilized in
0.1% NaOH containing NaDodSO4, and the radioactivity
was measured using a scintillation counter.
Materials. Highly purified PDGF was prepared as de-
scribed (37). EGF was purified and iodinated according to the
methods of Savage and Cohen (38) and Hunter and Green-
wood (39), respectively. PMA and cycloheximide were
obtained from Sigma, and cholera toxin was purchased from
Schwartz/Mann.
Abbreviations: PDGF, platelet-derived growth factor; EGF, epider-
mal growth factor; PMA, phorbol 12-myristate 13-acetate.
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RESULTS
Comparison of PDGF- and PMA-Induced Changes in 125I.
Labeled Binding. As shown in Fig. 1, cells treated with PDGF
exhibited a biphasic loss of 125I-labeled EGF binding capac-
ity. 1251I-labeled EGF binding decreased to approximately
30% of control with 5-15 min of treatment, increased to 50%
by 45-60 min, and, between 1 and 3 hr, declined from 50%
to 25% (see also Fig. 4). Higher concentrations ofPDGF did
not alter the extent of these reductions (data not shown).
EGF binding was also rapidly but transiently reduced by
PMA. The response elicited by PMA during the first hour of
treatment was greater than, but qualitatively similar to, that
observed with PDGF. In contrast to results obtained with
PDGF, in the PMA-treated cells 125I-labeled EGF binding did
not decline after 60 min but instead continued to increase for
at least 7 hr (Fig. 1 and data not shown). PDGF, therefore,
differs from PMA in its ability to effect a secondary decrease
in 125I-labeled EGF binding.
When PDGF and PMA were added to cells in combination,
125I-labeled EGF binding was reduced to a greater extent than
was maximally achieved by either agent alone (Fig. 1).
Furthermore, the recovery observed in cells treated with
PMA alone did not occur in cells receiving both agents.
Scatchard analysis of binding data indicated the loss of high
affinity EGF receptors in response to PDGF or PMA (data
not shown). Whether this loss resulted from the internaliza-
tion of receptors or from the conversion of high affinity
receptors to low affinity receptors could not be ascertained
from these plots.
Effect of PDGF on 125I-Labeled EGF Binding in PMA-
Pretreated Cells. Because PDGF and PMA do not affect EGF
binding in an identical manner, the mechanism by which
these agents act may differ, at least in part. The data
presented in Fig. 2 show that PDGF reduces EGF binding in
cells desensitized to PMA, which supports this hypothesis.
Quiescent cultures were treated for 20 hr with 600 nM PMA
under conditions nonpermissive for cell cycle traverse.
Chronic exposure of cells to high levels of PMA has been
shown to result in (i) the loss of detectable protein kinase C
activity (40) and (ii) the consequent loss ofPMA response (21,
41-44). Twenty hours after the addition ofPMA to quiescent
cells, 125I-labeled EGF binding had returned to 93% of control
level (Fig. 2). Incubation of these cells with fresh PMA for 15
min or 3 hr produced only a 6-10% reduction in binding
activity; in comparison, the 125I-labeled EGF binding in
control nonpretreated cells exposed to PMA was reduced










FIG. 1. Effect of PDGF or PMA on EGF binding. Density-
arrested BALB/c 3T3 cells were incubated at 37TC in medium alone
(A) or medium containing PDGF (25 ng/ml, o), 500 nM PMA (A), or
both (A). At various times after refeeding, the cells were rinsed with
binding medium and 125I-labeled EGF binding was determined at 4°C.
The amount of 125I-labeled EGF specifically bound by quiescent
cultures that were not refed represents 100%.
decreased 1251-labeled EGF binding to a similar extent and in
a biphasic manner in both control and PMA-pretreated
cultures.
In agreement with the findings of Coughlin et al. (45) and
Collins and Rozengurt (44), PMA-pretreated cells remained
mitogenically responsive to PDGF. When challenged with
PDGF in the presence of platelet-poor plasma, these cells
incorporated increased amounts of [3H]thymidine compara-
ble to that of control cells (Table 1). Although PMA stimu-
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FIG. 2. Effect of PDGF or PMA on control
or PMA-pretreated cells. Quiescent cultures
were incubated for 20 hr in medium supplement-
ed with 0.25% platelet-poor plasma and 600 nM
PMA. PMA-pretreated (9 and closed bars) or
nontreated control (o and open bars) cells were
refed with medium containing PDGF at 25 ng/ml
(Left) or 600 nM PMA (Right). 125I-labeled EGF
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Table 1. Effect of PDGF or PMA on mitogenic response of







Cultures were pretreated with PMA as described in the legend to
Fig. 2. The cells were then refed with medium containing
[3H]thymidine and either PDGF or PMA. Twenty-four hours later,
the amount of radioactivity incorporated into DNA was assessed.
Baseline incorporation was 26,256 cpm per well.
lated DNA synthesis in control cells as efficiently as did
PDGF, the addition ofPMA to PMA-pretreated cells did not
elicit a proliferative response. Thus, under conditions in
which PMA is rendered ineffective, PDGF is capable of
inducing both DNA synthesis and changes in 125I-labeled
EGF binding capacity.
Cholera Toxin Potentiation of the PMA-Induced Inhibition
of EGF Binding. Although PDGF and PMA affect EGF
binding dissimilarly and perhaps act via different mecha-
nisms, the actions of both agents are potentiated by cholera
toxin. The ability of this essentially irreversible activator of
adenylate cyclase to enhance the PDGF-induced inhibition of
EGF binding has been described (7, 36). The combined
effects ofcholera toxin and PMA on '25I-labeled EGF binding
are shown in Fig. 3. In these experiments, quiescent cultures
were preincubated with the toxin for 2 hr to maximally
elevate intracellular levels ofcyclic AMP (46); such treatment
did not affect cellular capacity to bind 125I-labeled EGF (ref.
7 and data not shown). When suboptimal amounts ofPMA (5
to 50 nM) were subsequently added to toxin-treated cells,
binding activity decreased at a faster rate and to a greater
extent than was observed in cells not exposed to cholera
toxin. Higher concentrations of PMA (500 nM) elicited a
rapid and maximum response and thus obscured these effects
of the toxin. At this concentration of PMA, however, an
additional effect of cholera toxin was evident-this agent
antagonized the recovery of binding activity that began at 1
hr in the control cells. Regardless of the dose of PMA or of
the presence of cholera toxin, '25I-labeled EGF binding
increased after 3 hr; binding activity, however, remained
lower in the toxin-treated cells (data not shown).
Dissociation of the Dual Effects ofPDGF on EGF Binding by
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FIG. 4. Recovery of EGF binding in the presence of cyclohexi-
mide. Cycloheximide was added to cells in "spent" medium to a final
concentration of 10 ug/ml. Fifteen minutes later, the cultures were
refed with medium containing PDGF at 25 ng/ml and cycloheximide
at 10 Ag/ml (e). Cells not preexposed to cycloheximide received
PDGF alone (o). 125I-labeled EGF binding was determined at various
times after refeeding. Cycloheximide at the concentration used
inhibited protein synthesis by greater than 95%.
EGF binding in the presence of cycloheximide was also
determined. The rapid loss of binding activity induced by
PDGF or PMA was unaffected by this inhibitor (Fig. 4 and
data not shown). In contrast, the secondary reduction in
1251-labeled EGF binding produced by PDGF did not occur in
cells also treated with cycloheximide; instead, binding ca-
pacity continued to increase, reaching approximately 90% of
control level by 3 hr. The difference in the cycloheximide
sensitivity of the initial versus the secondary decline in
125I-labeled EGF binding did not result from the turnover of
a protein(s) required for both effects, as treatment of cells
with cycloheximide for 2 hr prior to the addition ofPDGF did
not prevent the initial reduction (data not shown). These
findings suggest that PDGF may inhibit EGF binding via two
distinct processes that differ in their requirement for protein
synthesis.
FIG. 3. Enhancement by cholera toxin of the
PMA effect. Confluent cells were pretreated
with medium containing cholera toxin (1 ,ug/ml)
0 for 2 hr. Nontreated (0) and toxin-treated (e)
cells were then refed with medium supplement-
ed with 5 nM (Left), 50 nM (Middle), or 500 nM
(Right) PMA; cells preexposed to cholera toxin
also received the toxin at 1 ug/ml. 1251-labeled
2 3 EGF binding activity was measured at various
intervals after refeeding.
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DISCUSSION
Comparison of the effects ofPDGF and PMA on EGF binding
in density-arrested BALB/c 3T3 cells revealed both similar-
ities and differences. Both agents caused a rapid, transient,
cycloheximide-independent reduction in EGF binding capac-
ity. The actions of both agents, as shown here and in a
previous report (7), were potentiated by cholera toxin.
However, whereas PMA allowed binding activity to recover,
PDGF induced a secondary and cycloheximide-dependent
decline in binding capacity. Moreover, PDGF decreased
EGF binding under conditions in which PMA was rendered
ineffective.
The pattern ofEGF binding observed in BALB/c 3T3 cells
exposed to PMA (Fig. 1) is similar to that described for
PMA-treated KB (29), Rat-1 (25), and mouse embryonal
carcinoma (26) cells. Although the ability of PDGF to reduce
EGF binding is well documented (6-11, 47), to our knowl-
edge, the biphasic response described here (Fig. 1) has not
been reported before. Past studies on BALB/c 3T3 cells (7,
36) did not examine time points prior to 1 hr and thus
overlooked the initial effects of PDGF on EGF binding.
Although EGF binding was assayed as early as 10 min, and
for up to 2 hr, after addition of PDGF to Swiss 3T3 cells, the
loss of binding capacity produced by PDGF was continuous,
not biphasic (9). Thus, PDGF may alter EGF binding differ-
ently in different cell lines. Alternatively, if the increase and
decreases in EGF binding activity result from competing
processes, the ability of some cell types to effect one process
more efficiently than the other could obscure the biphasic
nature of the curve.
Previous studies have shown that prolonged exposure of
cells to PMA renders cells refractory to PMA (21, 41-44). As
demonstrated by Collins and Rozengurt (41) and Jaken et al.
(48), cellular desensitization to PMA is accompanied by a
dramatic decline in the number of binding sites for PMA. In
accord with the concept that protein kinase C is the receptor
for PMA, the activity of this enzyme in PMA-pretreated cells
is also reduced or absent (40). In our experiments, quiescent
BALB/c 3T3 cells were exposed to 600 nM PMA for 20 hr.
Cellular extracts prepared immediately and 3-4 hr after
exposure to PMA did not contain detectable protein kinase C
activity, as monitored by an endogenous phosphorylation
assay (data not shown). In contrast to results obtained with
control cells, the addition of PMA to PMA-pretreated cells
did not reduce EGF binding (Fig. 2) or stimulate DNA
synthesis (Table 1). Similarly, when challenged with PMA,
PMA-pretreated cells also did not synthesize CpI, a PMA- (or
PDGF-) inducible nuclear protein (refs. 49 and 50 and data
not shown). These data demonstrate that chronic exposure of
BALB/c 3T3 cells to high levels of PMA effectively abro-
gates cellular PMA responsiveness, presumably by effecting
the loss of protein kinase C activity. Furthermore, as de-
scribed above, the length of the pretreatment period was
sufficient to allow full recovery of EGF binding (Fig. 2).
The ability of PDGF to reduce EGF binding in cells
refractory to PMA (Fig. 2) suggests that the mechanism(s) by
which PDGF alters EGF binding differs from that of PMA
and thus, unlike that of PMA (51), is independent of protein
kinase C. This conclusion is supported by data showing that
the secondary decline of EGF binding induced by PDGF is
not observed in quiescent cells receiving PMA (Fig. 1).
However, because the initial reduction in binding produced
by PDGF is comparable to the PMA-induced reduction, the
involvement of a PMA-like mechanism in this action of
PDGF cannot be totally dismissed. For example, failure of
PMA-pretreated cells to phosphorylate endogenous sub-
strates does not exclude the possibility that residual kinase
activity remains that is not detectable in the assay. Although
residual kinase activity, if present, is insufficient for PMA to
affect EGF binding and mitogenesis, PDGF may be a more
efficient activator of the kinase than is PMA. However,
suboptimal, and thus less effective, concentrations of PDGF
reduced 125I-labeled EGF binding to comparable extents in
both control and PMA pretreated cultures (data not shown).
Alternatively, PDGF may activate a different kinase(s) that
phosphorylates EGF receptors at sites similar or identical to
those phosphorylated by protein kinase C.
The effects of PDGF on EGF binding have been reported
to be both inhibited by (9) and independent of (7) cyclohex-
imide. As shown here, the initial decline in binding activity
produced by PDGF was unaffected by cycloheximide,
whereas the secondary decrease was strictly dependent upon
continued protein synthesis (Fig. 4). This suggests that the
process affecting the secondary decline in EGF binding
differs from that responsible for the initial reduction and, in
addition, differs from that responsible for the cycloheximide-
independent loss of binding activity produced by PMA (data
not shown, ref. 29). However, the possibility that a single
mechanism mediates both actions of PDGF on '25I-labeled
EGF binding cannot be excluded-a factor(s) necessary for
both effects may be rapidly degraded in response to PDGF;
the initial decline in binding capacity would occur prior to its
turnover and the secondary decline would reflect its
resynthesis. The identity and function of the protein(s)
required by PDGF to reduce EGF binding are at present
obscure, and it is not known whether such protein(s) acts
intracellularly or is secreted into the culture medium.
Although PDGF and PMA do not inhibit EGF binding in an
identical manner, both agents enhance the mitogenic activity
of EGF in BALB/c 3T3 cells (2, 33) and in other cell lines (1,
3, 9). Whether the actions of these agents on EGF receptors
are causally related to their effects on EGF sensitivity is not
known; however, these events are correlated in many sys-
tems. For example, in addition to PDGF and PMA, other
agents that reduce EGF binding in Swiss 3T3 cells also act
synergistically with EGF to promote the proliferation ofthese
cells (17, 44, 52, 53). As shown here, PMA pretreatment did
not affect the ability of PDGF to alter EGF binding or
stimulate DNA synthesis. In contrast, the effects of vaso-
pressin on both of these processes were abrogated in Swiss
3T3 cells exposed to PMA (44). In BALB/c 3T3 cells, the
ability of PDGF to reduce EGF binding is potentiated by
cholera toxin, as in PDGF-induced competence formation
(45). Despite these correlations, however, a definitive rela-
tionship between heterologous receptor modulation and
mitogenesis has yet to be established.
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